louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01877304: Effect of Drug Targeting Nebulization on Lung Deposition
Official title: Effect of Drug Targeting Nebulization on Lung Deposition
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Subjects
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2013-06-13
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare deposition between two modalities of nebulization


Eligibility criteria: Inclusion Criteria:

* Free of respiratory disease

Exclusion Criteria:

* Smokers

Primary outcomes:
measure: Lung deposition by scintigraphy
timeFrame: After 15 minutes
Secondary outcomes:
measure: Regional deposition by scintigraphy
timeFrame: After 15 minutes
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Cliniques universitaires Saint-Luc
Study officials:
References:
Clinical trial NCT05362604: Prenatal Diagnosis of the Fetal Esophageal or Intestinal Atresia
Official title: Top Benefits of the Prenatal Diagnosis of the Fetal Esophageal or Intestinal Atresia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Antenatal Management of the Fetal Gastrointestinal Atresia
Lead sponsor: Poitiers University Hospital
Sponsor class: OTHER
First posted: 2022-05-05
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 51 mother-baby pairs

Brief summary: Aim- to investigate how prenatal diagnosis of fetal esophageal or intestinal atresia impacts obstetric and neonatal outcomes.

Methods- This was a retrospective cohort study at a single center. The study population comprised 51 consecutive pregnancies, including 29 mothers (57%) and their fetuses affected by prenatally diagnosed fetal esophageal or intestinal atresia, and 22 mothers (43%) and their babies with postnatally diagnosed fetal esophageal or intestinal atresia.

Detailed description: Aim- to investigate how prenatal diagnosis of fetal esophageal or intestinal atresia impacts obstetric and neonatal outcomes.

Methods- This was a retrospective cohort study at a single center. The study population comprised 51 consecutive participants, including 29 mothers (57%) and their fetuses affected by prenatally diagnosed fetal esophageal or intestinal atresia, and 22 mothers (43%) and their babies with postnatally diagnosed fetal esophageal or intestinal atresia.

Eligibility criteria: Inclusion Criteria:

* all pregnancies affected by fetal esophageal, duodenal or intestinal atresia referred to our prenatal diagnosis unit
* all newborns managed for such atresia in our unit of pediatric surgery

Exclusion Criteria:

* termination of pregnancy,
* stillbirth,
* the false positive cases

Primary outcomes:
measure: gestational age of delivery
timeFrame: 1 year
measure: mode of delivery
timeFrame: 1 year
Secondary outcomes:
measure: neonatal morbidity
timeFrame: 1 year
measure: length of hospital stay
timeFrame: 1 year
Other outcomes:
Locations:
city: Poitiers
country: France
facility: Centre Hospitalier Universitaire de Poitiers
Study officials:
References:
Clinical trial NCT01993004: Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells
Official title: Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
Lead sponsor: Rutgers, The State University of New Jersey
Sponsor class: OTHER
First posted: 2013-11-25
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Control human subjects and patients with RRMS will be enrolled in New Brunswick, NJ

Brief summary: MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and glatiramer acetate-treated patients with multiple sclerosis.

Detailed description: MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and glatiramer acetate-treated patients with multiple sclerosis. The expression of microRNA will be analysed in cell subsets separated from peripheral blood mononuclear cells.

Eligibility criteria: Inclusion Criteria:

18-60 year-old healthy subjects or patients with RRMS/CIS

Exclusion Criteria:

1. Any treatment with steroids in the last 30 days prior to the blood draw or any immunosuppressive or Disease-modifying treatment (DMT) other than Glatiramer Acetate in the last 90 days
2. Presence of other disorders that may be associated with immune-deficient or autoimmune process (e.g., HIV, lymphoma, lupus) or demyelinating disease other than MS (e.g., Lyme, B12 deficiency)
3. Pregnancy
4. Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk about 100 meters with or without resting (Expanded Disability Status Scale (EDSS) score greater than 5.5)

Primary outcomes:
measure: Relative MicroRNA expression in B cells
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: New Brunswick
country: United States
facility: Rutgers-RWJMS
state: New Jersey
Study officials:
affiliation: Rutgers-RWJMS
name: Konstantin Balashov, MD, PhD, FAAN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06644404: Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults
Official title: A Randomized, Open, Two-sequence, Crossover, Multiple Oral Administrations, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Drug-drug Interaction Between DWP16001, DWC202407, and DWC202408 in Healthy Adults
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Daewoong Pharmaceutical Co. LTD.
Sponsor class: INDUSTRY
First posted: 2024-10-16
Enrollment: 34
Sex: ALL
Minimum age (years): 19
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the pharmacokinetic/pharmacodynamic drug-drug interactions between DWP16001, DWC202407, and DWC202408 in healthy adults

Detailed description: This study aims to evaluate the pharmacokinetic interactions, pharmacodynamic interactions, safety, and tolerability of DWP16001, DWC202407, and DWC202408 in healthy adults

Eligibility criteria: Inclusion Criteria:

1. Healthy adult volunteers aged 19 to 50 years at the time of screening.
2. Individuals with a body weight between 50.0 kg and 90.0 kg and a Body Mass Index (BMI) between 18.5 kg/m² and 29.9 kg/m² at the time of screening.
3. Female volunteers must be neither pregnant nor breastfeeding, or must be in a surgically sterile state (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
4. Individuals who have been fully informed about the clinical trial, have fully understood the details, voluntarily decided to participate, and provided written consent to comply with the precautions.

Primary outcomes:
measure: Cmax,ss of DWP16001
timeFrame: 0-24 hours
measure: AUCtau,ss of DWP16001
timeFrame: 0-24 hours
measure: Cmax,ss of DWC202407
timeFrame: 0-12 hours
measure: AUCtau,ss of DWC202407
timeFrame: 0-12 hours
measure: Cmax,ss of DWC202408
timeFrame: 0-24 hours
measure: AUCtau,ss of DWC202408
timeFrame: 0-24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT05016401: Performance and Safety of Use of the "KONTACT PERIO LEVEL" Transgingival Titanium Dental Implant
Official title: Multicenter Observational Study Evaluating the Performance and Safety of Use of the "KONTACT PERIO LEVEL" Dental Implant in Routine Clinical Practice.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tooth Loss
Partially Edentulous Maxilla
Partially Edentulous Mandible
Lead sponsor: Biotech Dental
Sponsor class: INDUSTRY
First posted: 2021-08-23
Enrollment: 199
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patient eligible and planned for an implant-supported prosthetic restoration according to the instructions for use of the KONTACT PERIO LEVEL dental implant.

Brief summary: As part of post-marketing clinical follow-up, BIOTECH DENTAL sets up the collection and evaluation of clinical data proactively with the aim of confirming the safety, performance as well as the constantly acceptable nature of the risks identified and of detecting potential emerging risks with the use of "Kontact Perio Level" implants in everyday practice.


Eligibility criteria: Inclusion Criteria:

* Edentulous patient requiring the placement of one (or more) dental implant (s) in the maxilla or mandibular
* Age ≥ 18 years old
* Good general health (ASA score between \[1-2\])
* Sufficient volume and bone quality (with or without bone graft) to support the implant
* Non-objection of the patient for the collection of his medical data as part of the study

Exclusion Criteria:

* Poor oral hygiene
* Bruxism, parafunctional habits, occlusion disorders and / or temporomandibular joints
* Infections and oral inflammation such as active periodontitis, active gingivitis
* Patient with metabolic disorders (eg diabetes mellitus) or bone disease that may compromise peri-implant tissue healing
* Heavy smoker (\> 10 cigarettes / day)
* Patient with a pathology or immunosuppressive therapy such as chemotherapy, radiotherapy
* Patient on prolonged steroid therapy
* Titanium / titanium alloy allergy
* Alcohol or drug abuse
* Pregnant woman (or likely to be pregnant); or breastfeeding
* Difficulty of medical follow-up patients with geographical, social or psychological constraints
* Persons deprived of liberty or guardianship
* Involuntary / patient refusal to participate in the study

Primary outcomes:
measure: Success rate
timeFrame: 12 months
Secondary outcomes:
measure: Bone Level
timeFrame: 12 months
measure: Prosthetic complications
timeFrame: 12 months
measure: Primary stability
timeFrame: surgical time
measure: Survival rate
timeFrame: 12 months
measure: Factors that influence the survival and success rate
timeFrame: 12 months
measure: Peri-implantitis
timeFrame: 12 months
measure: Quality of Life
timeFrame: 12 months
Other outcomes:
Locations:
city: Bandol
country: France
facility: Coordinating Investigator
Study officials:
References:
Clinical trial NCT04539301: Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Official title: Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Anticoagulation
Venous Thromboembolism
Atrial Fibrillation
Keywords: Anticoagulants (MeSH)
Blood Coagulation Tests (MeSH)
Drug monitoring (MeSH)
Factor Xa Inhibitors (MeSH)
Heparin (MeSH)
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2020-09-04
Enrollment: 2100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients treated with apixaban or rivaroxaban or danaparoid or fondaparinux

Brief summary: Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay. The investigators aimed at assessing whether the widely used heparin anti-Xa assay can quantify the apixaban, rivaroxaban, fondaparinux and danaparoid levels.


Eligibility criteria: Inclusion Criteria :

* Blood sample from adult patients treated with apixaban or rivaroxaban or danaparoid or fondaparinux

Exclusion Criteria :

* Patients treated with unfractionated heparin or low molecular weight heparin

Primary outcomes:
measure: Agreement between measured and estimated levels of each factor-Xa inhibitor
timeFrame: 2 years
Secondary outcomes:
measure: Evaluation of the performance of the estimated anticoagulant level method by an inter-laboratory comparison program
timeFrame: 2 years
measure: Cost comparison (estimated anticoagulant level method versus specific dosage)
timeFrame: 2 years
Other outcomes:
Locations:
city: Nantes
country: France
facility: Nantes University Hospital
state: Loire-Atlantique
Study officials:
References:
Clinical trial NCT06845501: Purine Supplementation in Patients With AICA-Ribosiduria
Official title: PURICA : Purine Supplementation in Patients With AICA-Ribosiduria
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: AICA-ribosiduria Due to ATIC Deficiency
Keywords: AICA-Ribosiduria
ATIC
purine
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
Collaborators: name: University Hospital of Saint-Etienne
First posted: 2025-02-25
Enrollment: 10
Sex: ALL
Minimum age (years): 3
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: prospective, N-of-1 trial, comparative before/after study
Primary purpose: TREATMENT

Brief summary: AICA-Ribosiduria due to ATIC deficiency is a rare genetic metabolic disease that affects less than 10 patients (PMID: 32557644). It results in severe polyhandicap linked to neurodevelopmental disorders, visual impairment, growth retardation, severe spinal deformities and scoliosis, and often early-onset epilepsy. The disease is caused by dysfunction of the ATIC enzyme, which is involved in de novo purine biosynthesis. A recent study (PMID: 38244287) reported a decrease in disease biomarkers in a single patient after 3 months on a purine-rich diet, which persisted for at least 1 year. The investigators propose to replicate this study on several patients to investigate the potential of this treatment for this severe orphan disease.


Eligibility criteria: Inclusion Criteria:

* Individual affected by AICA-ribosiduria due to ATIC deficiency

Exclusion Criteria:

- Individual already on a purine-rich diet theoretical contraindication to a purine-rich diet

Primary outcomes:
measure: Urinary concentration
timeFrame: 6 months
Secondary outcomes:
measure: Number of hospitalizations
timeFrame: 12 months
measure: Quality of life score
timeFrame: 6 months
Other outcomes:
Locations:
city: Saint-etienne
country: France
facility: Chu Saint-Etienne
Study officials:
affiliation: Centre Hospitalier Universitaire de Saint Etienne
name: Francis RAMOND, doctor of medicine
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00081601: Study of CEP-701 in Treatment of Prostate Cancer
Official title: An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Prostate Cancer
Keywords: prostate cancer
prostate specific antigen
PSA
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2004-04-19
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.

Detailed description: A serological PSA response is defined as a reduction from baseline PSA serum concentration of at least 50%, which is confirmed by a second PSA value 28 or more days later.

Eligibility criteria: Inclusion Criteria:

* at least 18 yrs of age
* diagnosis of adenocarcinoma of the prostate
* no detectable metastatic disease as assessed by bone and CT scans
* has increasing serum PSA concentrations
* life expectancy of at least 3 months
* ECOG of 0 or 1
* has been withdrawn from antiandrogen therapy for at least 6 weeks prior to entering screening period

Exclusion Criteria:

* has asymptomatic disease
* has active GI ulceration or bleeding
* has been treated with non-hormonal systemic anticancer therapy or has received radiation within 4 weeks of baseline visit
* bilirubin \>2x ULN or ALT or AST \>2xULN or serum creatinine \>1.5mg/dL
* hemoglobin \<9g/dL or platelets below 100,000/uL or ANC below 1500/uL
* receiving treatment for HIV with protease inhibitors
* has had prior malignancy within past 5 yrs with exception of resected basal or squamous cell carcinomas of the skin
* has used investigational drug with previous one month

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins
state: Maryland
Study officials:
References:
Clinical trial NCT05588401: Evaluating Safety and Efficacy of Autologous Gene-edited Muscle Stem Cells (GenPHSats-bASKet)
Official title: Phase 1/2a First-in-human Trial Evaluating Autologous Gene-edited Muscle Stem Cells in Limb Girdle Muscular Dystrophies (GenPHSats-bASKet)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
PHASE2
Conditions: LGMD
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2022-10-20
Enrollment: 6
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: OTHER

Brief summary: This study is an investigator initiated first-in-human interventional open label phase 1/2a clinical trial investigating an ATMP in the orphan disease LGMD to evaluate safety and efficacy.

Detailed description: This trial is directed towards a first-in-human application of GenPHSats; gene edited primary human satellite cell derived muscle stem cells as a new Advanced Therapy Medicinal Product (ATMP) in a phase 1/2a clinical trial with Gene edited PHSats (GenPHSats) initiating healthy muscle development in patients with LGDM. The trial is set up to verify if GenPHSats can provide an therapy option for LGDM patients as there is currently no therapy available. The GenPHSats are an autologous product comprised of primary human satellite cell derived muscle stem cells obtained from the patient's own muscle tissue and gene edited in vitro prior to transplantation.

Eligibility criteria: Inclusion Criteria:

* LGDM diagnosed,
* Identified gene defect location and gene editing proved feasible,
* Age ≥14 years,
* Patient in treatment in the department at Charité, Universitätsmedizin Berlin, Muscle Research Unit and Outpatient Clinic for Muscle Disorders,
* Signed informed consent

Exclusion Criteria:

* Acute or chronic inflammatory local or systemic disease
* Coagulation disorder
* Known complications due to local anesthesia,
* Congenital heart defect, cardiac arrhythmia,
* Pathology of the airways such as micrognathia
* Pierre Robin Sequence
* Central hypoventilation syndrome/Ondine syndrome
* Significant other medical or psychiatric illness
* Positive serology for HIV and/or hepatitis A, B, C
* Pregnant or lactating women
* Known allergic reaction to constituents of the cryopreservation medium

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: Rate of muscle biopsy post-injection structure
timeFrame: 3 month post injection
Other outcomes:
measure: Rate of Muscle force
timeFrame: Until 6 month post injection
measure: Rate of Blood CK
timeFrame: Until 6 month post injection
Locations:
Study officials:
affiliation: Charite Universitätsmedizin Berlin, Germany
name: Simone Spuler, Prof Dr med
role: STUDY_CHAIR
References:
Clinical trial NCT04746001: Artificial Intelligence in the Diagnosis of Orthopaedic Conditions, Particularly Bone Tumours and Infection
Official title: Artificial Intelligence in the Diagnosis of Orthopaedic Conditions, Particularly Bone Tumours and Infection
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Bone Tumours
Bone Infection
Prosthetic Joint Infection
Prosthetic Infection
Lead sponsor: Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust
Sponsor class: OTHER_GOV
Collaborators: name: Keele University
First posted: 2021-02-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with suspected orthopaedic infection (including prosthetic joint infection) or bone tumours

Brief summary: Translational research aimed at improving diagnostic accuracy of musculoskeletal infection and musculoskeletal tumours using machine learning applied to clinical data, histopathological sections and genomic sequencing.


Eligibility criteria: Inclusion Criteria:

Suspected infection of bone tumour and biopsy taken for analysis

Exclusion Criteria:

Patient doesn't consent

Primary outcomes:
measure: Sequencing data and identification
timeFrame: 3 years
measure: Histological slides and identification
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Oswestry
country: United Kingdom
facility: Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust
state: Shropsire
Study officials:
References:
Clinical trial NCT00267501: Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
Official title: Eosinophils and Inflammation, an Expanded Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Eosinophilic Gastrointestinal Disease Eosinophilic Inflammatory Disease
Food Allergy
Keywords: Eosinophilic Disorders
Lead sponsor: Children's Hospital Medical Center, Cincinnati
Sponsor class: OTHER
First posted: 2005-12-21
Enrollment: 5000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with eosinophilic disorders and patients without eosinophilic disorders to serve as normal controls

Brief summary: The purpose of this study is to elucidate the mechanisms underlying eosinophil growth, survival, migration, and function and to investigate and further characterize the pathophysiology of, clinical manifestations of, and spectrum of disease severity of eosinophilic inflammation in humans.


Eligibility criteria: Inclusion Criteria:

* Signed informed consent obtained from the patient or parent/guardian. Assent will be obtained from all minors 11 years of age and older.
* Carrying a diagnosis of eosinophilic gastrointestinal disease, eosinophilic inflammatory disease, or food allergy OR family member, or normal control

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center
state: Ohio
Study officials:
affiliation: Cincinnati Children&#39;s Hospital Medical Center
name: Marc E. Rothenberg, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: